BridgeBio Pharma (BBIO) Free Cash Flow Growth (3y) (2021 - 2026)
Powered by 
Analysis
BridgeBio Pharma (BBIO) Free Cash Flow Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -1.95% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -20.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 21.16% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 45.09% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 80.69% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -4.45% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 8.92% |
| 10 | BridgeBio Pharma | 14.65 Bn | 13.93 Bn | 228.63 Mn | 14.31% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 14.31% |
| Mar 31, 2026 | -10.97% |
| Dec 31, 2025 | 15.64% |
| Sep 30, 2025 | 6.80% |
| Jun 30, 2025 | -35.06% |
| Mar 31, 2025 | -7.31% |
| Dec 31, 2024 | -12.72% |
| Sep 30, 2024 | -12.17% |
| Jun 30, 2024 | 40.85% |
| Mar 31, 2024 | -12.98% |
| Dec 31, 2023 | -8.37% |
| Sep 30, 2023 | -3.28% |
| Jun 30, 2023 | -8.83% |
| Mar 31, 2023 | -17.78% |
| Dec 31, 2022 | -6.46% |
| Sep 30, 2022 | -39.21% |
| Jun 30, 2022 | 21.66% |
| Mar 31, 2022 | -39.44% |
| Dec 31, 2021 | -42.49% |
| Sep 30, 2021 | -48.71% |